Mats Jerkeman
171 – 180 of 181
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2004
-
Mark
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
(
- Contribution to journal › Article
- 2003
-
Mark
Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study.
(
- Contribution to journal › Article
- 2002
-
Mark
Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
- 2001
-
Mark
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
(
- Contribution to journal › Article
-
Mark
Expression of the B-cell transcription factor PU.1 is strongly correlated with CD10, CD79a, CD20, CD22, and bcl-6 expression in diffuse large B-cell lymphoma (DLBCL)
(
- Contribution to journal › Article
-
Mark
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial
(
- Contribution to journal › Article
- 2000
-
Mark
Residual mass in aggressive lymphoma--does size, measured by computed tomography, influence clinical outcome?
(
- Contribution to journal › Article
-
Mark
Aggressive lymphoma
2000)(
- Thesis › Doctoral thesis (compilation)
- 1999
-
Mark
Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas
(
- Contribution to journal › Article
-
Mark
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial
(
- Contribution to journal › Article